PRODUCTION OF ENGINEERED T CELLS FROM STEM CELLS

This disclosure provides methods for producing T cells with shortened ex vivo manufacturing time. In particular, this disclosure involves the production of T cells from hematopoietic stem cells with the proviso that the process does not involve subsequent in vitro steps of activation and/or expansio...

Full description

Saved in:
Bibliographic Details
Main Authors WIEZOREK, JEFFREY SCOTT, GOV, LANNY, ALLEN, SEAN, SMITHAKE, WANG, XI
Format Patent
LanguageEnglish
French
Published 17.11.2022
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:This disclosure provides methods for producing T cells with shortened ex vivo manufacturing time. In particular, this disclosure involves the production of T cells from hematopoietic stem cells with the proviso that the process does not involve subsequent in vitro steps of activation and/or expansion of the T cells. La présente divulgation concerne des procédés de production de lymphocytes T avec un temps de fabrication ex vivo raccourci. En particulier, la présente divulgation concerne la production de lymphocytes T à partir de cellules souches hématopoïétiques à condition que le procédé ne mette pas en jeu des étapes ultérieures in vitro d'activation et/ou d'expansion des lymphocytes T.
Bibliography:Application Number: CA20223220136